In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

A mother-of-two claims to have found a "miracle" cure for her psoriasis almost three decades after first being diagnosed with ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...